Welltower Inc. (WELL)
REIT de vivienda para adultos mayores y salud
The largest senior housing REIT in the United States, the United Kingdom and Canada (more than 2,500 properties), with occupancy recovering (85.1%→87.4% in 2025) and solid organic growth (Same-Store NOI in the operated segment +21.0%). But at $240 —near its 52-week high— reported FFO fell due to a real, one-time stock-based compensation charge (a cost the method always expenses, never adds back) and much of the recent growth is inorganic: base 5-year value $123 (-13%/year price, -10% with dividend): Overvalued.
- Price
- $240.38
- Intrinsic value (5y, base)
- $123
- Total annual return (5y)
- -10.4%
- Status (nominal)
- Overvalued
- Margin of safety
- No margin
The essentials
- The largest senior housing REIT in the world: more than 2,500 communities in the U.S., the United Kingdom (~20.0% of revenue) and Canada (~6.8%), with 62 operating partners and only 712 direct employees. Three segments: Seniors Housing Operating (~78% of revenue, mostly under the RIDEA structure), Triple-net (~11%) and Outpatient Medical (~7%, being divested).
- Recent growth (revenue +40.2% FY25, +43.5% TTM) is mostly inorganic: large acquisitions (Care UK, Barchester, HC-One) and an ongoing ~$7.2bn sale of the Outpatient Medical portfolio. The real organic engine —the one underpinning the valuation— is the segment-weighted Same-Store NOI, of approximately +17% per year.
- Reported FY2025 FFO ($1.818bn, -22% vs FY24) fell because of a real $1,409M stock-based compensation charge from the new ten-year executive continuity program — a cost the method always expenses. On that reported FFO, the current price implies a multiple above 90×; even taking as a reference the FFO excluding that one-off charge (a reading this analysis does not treat as a valid normalization of the cost, only as the starting point of the projected path), the multiple runs around 54× — on either reading, far above the reference range for a REIT.
Intrinsic value — two valuation methods
Total return at 5 years: -10.3%/year = -12.5% appreciation + 2.2% dividend. The target price ($123) is ex-dividend; the $20 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $231 · Multiples $116) is below the market price ($240).
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $240 trades ~107.3% above its value discounted to today (~$116); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$74.
Thesis
The business
Welltower is the largest senior housing REIT in the world, with a moat resting on scarce licensed locations, a proprietary data platform, a network of 62 operators and a balance sheet capable of funding large-scale acquisitions. Occupancy is recovering strongly (85.1%→87.4% in 2025) and Same-Store NOI in the operated segment is growing +21.0% — the underlying business is of high quality and benefits from a structural demographic tailwind (the silver economy).
The valuation
A REIT is valued on P/FFO, not P/E (real estate depreciation is not an economic cost). Reported FY2025 FFO ($1.818bn, $2.68/share, -22% vs FY24) fell due to a real $1,409M charge for stock-based compensation from the new executive continuity program and the ongoing sale of the Outpatient Medical portfolio. Stock-based compensation is a real cost —the method always expenses it, never adds it back—, so reported FFO is the correct figure: at $240 it implies an entry multiple of ~90×. This analysis takes as the path's year-0 the FFO excluding that one-time charge (~$3.227bn) only to isolate the business's recurring level, not as a valid normalization of the cost —which was paid regardless, through share dilution—; using that more favorable figure, the entry multiple at $240 is still ~51× — under either reading, far above the method's reference range for a REIT (P/FFO 15-20×). The base scenario projects aggregate FFO growing from the weighted organic growth rate (~17%, segment Same-Store NOI) plus already-closed acquisitions, decelerating to ~8% by year 5, with shares diluting from equity funding of acquisitions; the exit multiple compresses to 18× → $123/share, a price CAGR of -13%, -10% with the dividend (1.4%).
The margin of safety
No margin of safety: the price already discounts a demanding scenario. The market price (near its 52-week high) already prices in a continuation of the recent growth pace that is largely inorganic (acquisitions funded with debt and share issuance), on top of reported FFO that also carried a real, one-time stock-based compensation charge —which the method always expenses— and reduced the year's FFO per share. Applying the method's reference range for a REIT (P/FFO 15-20×) to the year-0 FFO used in the path and projected with organic growth, the verdict is Overvalued: the business is high quality, but the price leaves no margin under any reading of FFO.
What to watch
The central disconfirming test: if Same-Store NOI in the operated segment (+21.0% in 2025) sustains that pace beyond the post-pandemic occupancy recovery, real organic growth could exceed this analysis's normalized path and the verdict would be revised upward. In the opposite direction: watch whether the executive compensation charge recurs (the program runs ten years, and only part of it was recognized in 2025), whether the pace of dilution from share issuance keeps funding acquisitions at the same rate, and the impact of the Medicaid reimbursement cut (OBBBA, starting 2028) on operators' ability to pay.
Educational / informational. Does not constitute investment advice.